@ANDREWHESSELJULY 31 02010

a drug company for everyone

PINK ARMY COOPERATIVE

http://ilovebacteria.com/Images/bacterialcell.jpg http://i.dell.com/images/global/products/314x314/desktop-studio-mini-left-314.jpg

5

andrew hessel

COMPILE

DESIGN

design/build/design/build/test cycletest cycle

EXECUTE

TEST

applications

David Appleyard

CANCER

CANCER R&D IS

Evolutionary distance

~ 4 billion yearstwo completely different species, far

removed,and bacteria are clonal

many chemical compounds have antimicrobial activity without seriously harming human cells

Evolutionary distance

max: patient’s agecancer cells are same species,

only recently diverged, and every divergence is unique, cells

continue to degrade over time (mixed)

photo by billy hunt

christa slotboom

TARGETING FAST GROWING CELLS IS SO 1950there are plenty of normal cells that grow fast too, making treatments

needlessly harsh

ONE-SIZE-FITS-ALL DRUGMAKING IS ILLOGICALeach person’s DNA is different, their mutations are different, cancers are of

mixed cell types

CANCER RESEARCHERS DON’T MAKE DRUGS drug companies make drugs

A LOT OF RESEARCH ISN’T USEFUL there appears to be a near-infinite number of paths to cancer

CHANGE IS HARDcancer is industry with tremendous inertia

THE IDEAL THERAPEUTIC

specific to the cancergentle

effectivemade quicklyinexpensive

http://www.nature.com/horizon/chemicalspace/background/images/odyssey-f1.jpg

Scientists

newdrug X

shareholders

Lawyers

MANUFACTURERS

clinical trials

Economists

physicians

Insurance companie

s

geneticists

system is inherently limitedrequires blockbustersunable to accelerate

RISK vs BENEFIT (n>1)

STATISTICAL ANALYSIS OF POPULATIONSrequires large markets failure is expensive politicalslow

RISK vs BENEFIT (n=1)

no statistics – just direct observationsrisk benefit analysis always an individual decision

?

isolate and

analyzedesign build test

failures

provide and

evaluate

SYNTHETIC BIOLOGY BIOFAB

results

COOPERATIVE

data sharing

aims to bring together researchers, developers, cancer sufferers and supporters in a self-funded,

open-source therapeutic venture

goal:not a new drug, but a completely new way

of making drugs

one that can accelerate and improve over time

a significant step towards faster, better, cheaper cancer drugs

+ =

diagnostics today, treatments tomorrow

pinkarmy.orgjoin us